Frankenfield Christopher James
Insider CIK 1988344 · XLO Chief Operating Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics, Inc. | S Sale | 2026-01-02 | 2026-01-05 | 7,030 | $0.64 | $4.5K | 24,766 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise deriv | 2026-01-01 | 2026-01-05 | 19,375 | — | $0 | 38,750 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise | 2026-01-01 | 2026-01-05 | 19,375 | — | $0 | 31,796 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-12-31 | 2026-01-05 | 668,789 | — | $0 | 668,789 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 37,296 | — | $0 | 37,296 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 37,296 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 45,000 | — | $0 | 45,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 20,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 117,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 117,000 | — | $0 | 117,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 150,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 300,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 300,000 | — | $0 | 300,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 925,000 | — | $0 | 925,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 155,090 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 155,090 | — | $0 | 155,090 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 23,786 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 23,786 | — | $0 | 23,786 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 45,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-04-15 | 2025-04-16 | 75,000 | — | $0 | 75,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | S Sale | 2025-01-02 | 2025-01-03 | 6,954 | $0.98 | $6.8K | 12,421 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise deriv | 2025-01-01 | 2025-01-03 | 19,375 | — | $0 | 58,125 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-01-01 | 2025-01-03 | 251,000 | — | $0 | 251,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise | 2025-01-01 | 2025-01-03 | 19,375 | — | $0 | 19,375 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2024-08-03 | 2024-08-06 | 52,000 | — | $0 | 52,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2024-05-01 | 2024-05-03 | 208,000 | — | $0 | 208,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2024-01-01 | 2024-01-03 | 77,500 | — | $0 | 77,500 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2023-08-16 | 2023-08-18 | 300,000 | — | $0 | 300,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2023-08-03 | 2023-08-07 | 150,000 | — | $0 | 150,000 | SEC↗ |